从斯库拉到卡律布狄斯：在印度，固定剂量复合药物治疗结核病和乙胺丁醇引起的视神经病变增加。

From Scylla to Charybdis: Fixed drug combinations for tuberculosis and increased ethambutol-induced optic neuropathy in India.

机构信息

Department of Internal Medicine, L V Prasad Eye Institute, Hyderabad, Telangana, India.

Department of Retina and Vitreous, L V Prasad Eye Institute, Vijayawada, Andhra Pradesh, India.

出版信息

Indian J Ophthalmol. 2022 Aug;70(8):3073-3076. doi: 10.4103/ijo.IJO_3082_21.

DOI:10.4103/ijo.IJO_3082_21

PMID:35918975

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9672794/

Abstract

PURPOSE

To describe the increase in prevalence of ethambutol-induced optic neuropathy (EON) in patients presenting to a single tertiary referral eye care center in India after introduction of weight-based fixed dose combinations and an increase in duration of ethambutol use from 2016 in the Revised National Tuberculosis Control Program.

METHODS

This was a retrospective, observational, referral hospital-based study of 156 patients with a diagnosis of EON presenting to a single tertiary referral eye care center between January 2016 and December 2019. The main outcome measure was to assess the increase in prevalence of EON cases presenting to our tertiary care institute.

RESULTS

During the 4-year study period, 156 new patients were diagnosed with EON. A total of 101 patients (64.7%) were males and 55 (35.3%) were females. The most common age group affected was 41-60 years. The significant complaint at presentation was decreased vision in all the patients. A rising trend in the number of patients diagnosed as EON was seen, with the prevalence increasing from 16 cases in 2016, 13 cases in 2017, and 31 cases in 2018 to 96 cases in 2019.

CONCLUSION

The results of this study indicated an alarming increase in the trend of EON cases presenting to our tertiary care institute.

摘要

目的

描述在印度，由于采用了基于体重的固定剂量组合，并将乙胺丁醇的使用时间从 2016 年修订的国家结核病控制规划中延长，导致在单一的三级转诊眼科中心就诊的患者中，乙胺丁醇诱导的视神经病变（EON）的患病率增加。

方法

这是一项回顾性、观察性、转诊医院的研究，共纳入了 156 例在 2016 年 1 月至 2019 年 12 月期间在单一的三级转诊眼科中心就诊的 EON 患者。主要观察指标是评估在我们的三级治疗机构就诊的 EON 患者的患病率增加情况。

结果

在 4 年的研究期间，共诊断出 156 例新的 EON 患者。其中，男性 101 例（64.7%），女性 55 例（35.3%）。受影响的最常见年龄组为 41-60 岁。所有患者的主要症状均为视力下降。随着 EON 患者数量的增加，呈现出上升趋势，患病率从 2016 年的 16 例、2017 年的 13 例、2018 年的 31 例增加到 2019 年的 96 例。